Halozyme Therapeutics, INC 8-K filings

Halozyme Therapeutics announced record second quarter 2026 results, exceeding estimates with a 48% year-over-year revenue increase and raising its full-year financial guidance.

Halozyme Therapeutics announced robust first-quarter 2026 financial results, driven by significant revenue growth, and initiated a new $1 billion share repurchase program.

Halozyme Therapeutics, Inc. reported on its Annual Meeting of Stockholders held on May 5, 2026, where key proposals including director elections and executive compensation were approved.

Halozyme Therapeutics announces the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026, bringing extensive financial leadership experience from Johnson & Johnson.

Halozyme Therapeutics amended its bylaws to clarify director removal procedures and prohibit stockholder action without a meeting.

Halozyme Therapeutics, Inc. announced the appointment of David Ramsay, a former CFO, as its Interim Chief Financial Officer, effective March 23, 2026.

Halozyme Therapeutics announced raised financial guidance for 2026 and updated preliminary 2025 estimates, alongside the acquisition of Surf Bio for its hyperconcentration technology.

Halozyme Therapeutics' CEO, Dr. Helen Torley, received a $10 million performance-based restricted stock unit grant tied to significant stock price appreciation over four years.

Halozyme Therapeutics, Inc. announced the election of James Lang to its Board of Directors, effective December 4, 2025.

Halozyme Therapeutics, Inc. has finalized a transition and release agreement with its departing Chief Financial Officer, Nicole LaBrosse, outlining her departure benefits.

Halozyme Therapeutics, Inc. completed a $1.5 billion convertible senior notes offering to refinance existing debt and fund strategic initiatives.

Halozyme Therapeutics announced the pricing of $1.3 billion in convertible senior notes due 2031 and 2032, with an option for an additional $200 million, primarily to repurchase existing convertible notes.

Halozyme Therapeutics amended its credit facility to $750 million and announced a proposed offering of $1.3 billion in convertible senior notes to refinance existing debt and for general corporate purposes.

Halozyme Therapeutics reported record third-quarter financial results and raised its full-year 2025 guidance, driven by strong royalty revenue growth and strategic product approvals.

Halozyme Therapeutics projects zero to minimal impact on its future royalty revenue from the U.S. Centers for Medicare & Medicaid Services' final IPAY 2028 guidance for Medicare Part B price negotiations.

Halozyme Therapeutics, Inc. announced the appointment of Cortney Caudill as Senior Vice President, Chief Operating Officer, effective October 1, 2025.

Halozyme Therapeutics announced an agreement to acquire Elektrofi, Inc. for an upfront cash payment of $750 million, with potential additional milestone payments of up to $150 million.

Halozyme Therapeutics announced a definitive agreement to acquire Elektrofi, a biopharmaceutical company specializing in ultra-high concentration microparticle technology, for an upfront payment of $750 million and up to $150 million in milestone payments.

Halozyme Therapeutics reported strong second quarter 2025 financial results, driven by significant royalty revenue growth, and subsequently raised its full-year 2025 financial guidance ranges.

Halozyme Therapeutics reports a strong first quarter in 2025, leading to increased financial guidance for the year and a new $250 million share repurchase program.

Halozyme Therapeutics successfully held its Annual Meeting of Stockholders on May 1, 2025, electing directors and ratifying the selection of Ernst & Young LLP as its independent auditor.

Michael J. LaBarre, Senior Vice President and Chief Technical Officer of Halozyme Therapeutics, retired from the company effective March 17, 2025.

Halozyme Therapeutics announces record full year 2024 revenue of $1.015 billion, exceeding financial guidance for royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS.

Connie L. Matsui, a member of Halozyme Therapeutics' Board of Directors, will not seek reelection at the company's 2025 annual meeting of stockholders.

Halozyme Therapeutics has increased its 2025 financial outlook, projecting significant revenue and earnings growth, while also announcing a new $250 million share repurchase program.

Halozyme Therapeutics announced a 34% year-over-year increase in total revenue and a 67% increase in net income for the third quarter of 2024, leading to an increased financial outlook for the year.

Halozyme announced robust second quarter 2024 financial results, highlighted by a 12% year-over-year increase in royalty revenue and a net income of $93 million.

Halozyme Therapeutics announced a 21% year-over-year increase in revenue to $196 million for the first quarter of 2024, alongside a new $750 million share repurchase program.

Halozyme Therapeutics held its annual meeting, electing two Class II directors, approving executive compensation, amending its certificate of incorporation, and ratifying its accounting firm.

Halozyme Therapeutics reported a 27% year-over-year increase in fourth-quarter revenue and announced a new $750 million share repurchase program, while reiterating its 2024 financial guidance.